{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-060747","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2026-05-14T12:50:28+00:00","discovered_at":"2026-05-14T12:55:00.687984+00:00","generated_at":"2026-05-14T12:55:23.627435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dogwood Q1 net loss $5.0M; Halneuron Phase 2b data due fall 2026","bullets":["Net loss of $5.0M ($0.15 per share) vs $12.2M ($8.45) in Q1 2025; R&D $2.7M, G&A $2.4M.","Cash $13.2M provides runway into Q4 2026; closed $12.5M of a $26.9M financing in Jan 2026.","Halneuron Phase 2b in CINP: 164 enrolled, top-line results expected fall 2026.","SP16 IND approved; Phase 1b in CIPPN funded by NCI, enrollment starts mid-2026.","Announced global partnership for legacy antiviral assets with potential value up to $100M to Dogwood and shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-060747","json":"https://secwatch.observer/filing/0001104659-26-060747.json","markdown":"https://secwatch.observer/filing/0001104659-26-060747.md","text":"https://secwatch.observer/filing/0001104659-26-060747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926060747/0001104659-26-060747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926060747/dwtx-20260514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:55:23.627435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}